Printer Friendly

Visiogen, Inc. Receives FDA Approval to Expand its U.S. Clinical Trial.

Expansion of Trial Will Allow Researchers to Further Validate Safety and Effectiveness of the Investigational Synchrony[R] Dual Optic Accommodating IntraocularLens

IRVINE, Calif. -- Visiogen, Inc. of Irvine, California, announced it

has received approval from the U.S. Food & Drug Administration (FDA) for full expansion of its Phase III U.S. clinical trial for its Synchrony[R] dual optic accommodating intraocular lens. Already approved for use throughout the European Union, the Synchrony system is being studied in a multi-center trial in the U.S. to evaluate safety and effectiveness and the potential for near and intermediate vision without the use of spectacles in patients post cataract surgery.

"Full expansion of the clinical trial for Synchrony is another significant step toward our ultimate goal of approval for use within the United States," according to Barbara Niksch, Vice President of Regulatory, Quality & Clinical Affairs at Visiogen.

The proprietary Synchrony system, intended for use in cataract and refractive patients, incorporates a dual optic lens with an easy-to-use pre-loaded injector. The entire system is self-contained and ready for use without the need for lens handling. The dual optic lens can be inserted through a 3.6 - 3.8 mm clear-corneal incision. The single-piece silicone lens unfolds in the eye upon insertion and features two optics connected by a spring system. The springs connect a 5.5-mm high power anterior optic and a 6-mm negative power posterior optic; the spring action moves the front optic and changes the eye's focus from near to far. This unique combination of positive- and negative-powered optics is customized for each patient.

To date, the Synchrony lens has been implanted in over 400 patients worldwide. The company announced that it had received the European CE Mark for the Synchrony[R] Dual Optic Accommodating IOL in June of 2006, which allows them to expand into post-marketing research studies within Europe to further build the scientific foundation for Synchrony.

About Visiogen

Visiogen, Inc. is focused on developing innovative products for cataract and refractive patients. Founded in Irvine, California, in 2001, Visiogen's first commercial application, Synchrony[R], a dual optic accommodating intraocular lens and pre-loaded injector, is currently in clinical studies in the U.S. and recently received the CE Mark in Europe.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 17, 2007
Previous Article:Research & Markets: Gain an Insight into the Financial Performance of Ixia.
Next Article:Research and Markets : Leading Auto Components Manufacturer Arvinmeritor Profiled in New Report.

Related Articles
Serono seeks FDA approval for Rebif. (News).
InSite Vision to Hold Conference Call to Discuss Top Line Results of Second Phase 3 Clinical Trial on Tuesday, March 14th.
invivodata Announces Expanded Services From PRO Consulting; Extended Team of Scientific and Regulatory Experts Ensure Data Integrity in Clinical...
Savient Receives FDA Final Approval for Puricase (PEG-uricase) Phase 3 Special Protocol Assessment (SPA); Patient Dosing to Begin in May.
CVBT Achieves Safety Milestone in Clinical Heart Trial.
Ventracor Investor Update March 2007.
FDA Approves Oscient Pharmaceuticals' FACTIVE(R) Tablets for Five-Day Treatment of Community-Acquired Pneumonia.
Emergent BioSolutions Files Investigational New Drug Application With FDA for Pivotal Anthrax Immune Globulin Clinical Trial.
Delcath Systems Receives National Cancer Institute Approval to Expand Phase III Trial to Multiple Centers.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters